Decoding Tumor Heterogeneity through Multi Omics: Insights into Cancer Evolution, Microenvironment and Therapy Resistance
Paul-Miki Raluchukwu Ibekwe
Isenberg School of Management and Institute for Applied Life Sciences, University of Massachusetts - Amherst, MA, US.
Elizabeth Anuoluwa Akintayo
Department of Bioengineering and Biomedical Engineering, Wayne State University, 45 Warren Ave, Detroit, MI, USA.
Cecilia Ndiuwem Okuku
Department of Chemical Pathology, University of Uyo, Uyo, Akwa Ibom State, Nigeria.
Ismaila Muhammed
Department of Mathematics, Khalifa University, Abu Dhabi, United Arab Emirates.
Fuhad Mayowa Jeje
Department of Community Health and Primary Health Care, Lagos State University College of Medicine, Lagos State, Nigeria.
Okun, Oseghale
Medical Laboratory Services, Federal Neuro-Psychiatric Hospital, Benin City, Edo State, Nigeria.
Kemiki Olalekan Ademola
Molecular and Tissue culture laboratory, Babcock University Teaching Hospital, Ogun state, Nigeria.
Muhydeen Damilola Badru
Department of Haematology and Immunology, Obafemi Awolowo University, Ile-Ife, Nigeria.
Lydia Amarachi Onwuemelem
*
Department of Medical Laboratory science, University of Benin, Nigeria.
*Author to whom correspondence should be addressed.
Abstract
Background: The existence of genetically, epigenetically, and phenotypically distinct cell populations inside and between tumors is known as tumor heterogeneity, and it is one of the main barriers to effective cancer treatment. This intricacy affects the likelihood of metastasis, therapeutic resistance, and disease recurrence, rendering single-omics methods and conventional diagnostics inadequate for whole-tumor profiling. As a result, multi-omics methods, which incorporate data from multiple biological layers, such as transcriptomics, proteomics, metabolomics, genomes, and epigenomics, have emerged as powerful tools for thoroughly examining intra- and inter-tumoral complexity.
Methods: A comprehensive literature synthesis was conducted, emphasizing high-impact studies that illustrate technological innovation and translational impact in multi-omics applications. Key case studies in glioblastoma, non-small cell lung cancer, and breast cancer are highlighted to demonstrate real-world clinical relevance.
Aims and Objectives: This paper explores the ways in which integrated multi-omics has transformed our understanding of clonal dynamics, tumor growth, and resistance mechanisms while charting a path toward precision oncology.
Key Insights: The latest methods, such as single-cell multi-omics, spatial transcriptomics, and proteogenomics, were examined, along with computational frameworks including network-based models, probabilistic inference algorithms, and AI-driven tools that make it easier to integrate high-dimensional data. Along with discussing new technologies like in vivo biosensors, organoid-based modeling, and point-of-care omics, the function of the tumor microenvironment, lineage tracing, and liquid biopsies in monitoring the real-time progression of tumors was also discussed. Translational hurdles, including cost, complexity, and ethical issues were addressed while highlighting the importance of equity and worldwide access.
Conclusion: Multi-omics has great promise for truly personalized oncology by providing the integrated insights required for dynamic monitoring, predictive diagnosis, and tailored therapy design in future cancer care.
Keywords: Heterogeneity, multi-omics, therapy resistance, tumor microenvironment, personalized oncology